Temasek invests US$250m in China health care venture
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[SINGAPORE] Temasek Holdings Pte is investing US$250 million in the China operations of Columbia Pacific Management, as Singapore's state-owned investment firm expands its health care holdings.
Temasek and Columbia will form a 50-50 joint venture aimed at providing China's growing middle-class population with affordable health care services, Seattle-based Columbia said in a statement.
The partnership will enable Columbia China to further expand in China through acquisitions and new projects, according to the statement.
During its latest financial year ended March 31, Temasek loaded up on stakes in US pharmaceutical and health-care firms including Alexion Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc, which develop treatments for serious medical conditions.
The share of life sciences and agriculture-related assets in Temasek's portfolio has doubled to 4 per cent in the two years ending March 31, according to its website.
BLOOMBERG
Share with us your feedback on BT's products and services
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
